To our knowledge, there are two clinical studies that have evaluated the combination of mTOR inhibitors with a hypomethylating agent, reported by Liesveld et al. and Tan et al. Liesveld et al. evaluated decitabine followed by sirolimus in an open label, single arm, Phase 1 dose escalation study in relapsed/refractory AML [263]. The gene discussed is MTOR; the disease is acute myeloid leukemia.